| | First author | Year | Subtype | Prognostic models | AUC (95% CI) | C-index (95% CI) | HR (95% CI) |
| | Bao [60] | 2014 | Glioma | RAB1A, BIRC5, TEAD2, TUBA1B, MT1E, SFXN4, TPX2, HDAC4, and FAM125B | NA | NA | NA | | Bingxiang [61] | 2021 | GBM | G6PC2, STC1, HDAC4, COG2, SRD5A3, MDH2, IL13RA1, TGFBI, and B3GAT3 | 1 year: 0.745 | 3 years: 0.763 | — | NA | 1.783 (1.496-2.125) | | Chen [62] | 2016 | LGG | HOXA7, SLC2A4RG, and MN1 | CGGA: 0.869 (0.774-0.964) | TCGA: 0.785 (0.707-0.863) | — | NA | CGGA: 2.606 (1.690-4.018); TCGA: 3.384 (2.085-5.492) | | Fan [63] | 2021 | GBM | CLEC5A, HOXC6, HOXA5, CCL2, GPRASP1, BSCL2, and PTX3 | TCGA training: 0.721 | TCGA test: 0.688 | CGGA: 0.692 | NA | TCGA set: 3.77 (2.05-6.92) | | Hou [64] | 2019 | GBM | CCL7, CPNE9, GUCA1A, HOXA11, HOXC11, HOXD11, INSL3, KHDRBS2, KRT19, MEPE, MLPH, NELL1, TBX5, and TMEM233 | TCGA training set: 0.975 | CGGA testing set1: 0.907 | GSE13041 testing set 2: 0.905 | NA | NA | | Jia [65] | 2021 | IDH-mutant glioma | MTIF3, ITGB7, IGSF5, HNRNPA3P1, HMGA1, GJA5, FANCL, FANCB, F5, ESR2, EFNA1, DCBLD1, CYP3A5, CD97, CCRL1, CCNY, CCDC157, C4orf3, C1orf51, C1orf187, C18orf10, C15orf42, AURKAPS1, ARF1, ANKRD20A3, ALS2CR4, ALMS1P, ADD3, ADAMTS7, ADAMTS13, and ACAD11 | 0.9315 | NA | NA | | Li [66] | 2021 | LGG | RFWD3, MPHOSPH9, WRN, and NUP155 | Training set: 1 year: 0.796; 3 years: 0.710; 5 years: 0.601 | Validation set: 1 year: 0.668; 3 years: 0.655; 5 years: 0.655 | — | NA | NA | | Li [67] | 2020 | Grade II/III glioma | HCK, HAVCR2, CD37, LPAR5, NAGA, C1QC, FCER1G, and AIF1 | TCGA: 0.80 | NA | TCGA: 2.713 (1.675-4.394); CGGA part C dataset: 1.958 (1.158-3.310) | | Lin [68] | 2020 | Glioma | TAGLN2, PDPN, TIMP1, and EMP3 | TCGA: 0.80 (0.76–0.83) | CGGA: 0.72 (0.68–0.76) | — | NA | TCGA: 1.07 (1.06–1.08); CGGA: 1.19 (1.16–2.23) | | Pan [69] | 2020 | GBM | GRIA2 and RYR3 | GSE16011 dataset: 2 years: 0.671 (0.58-0.762); 3 years: 0.736 (0.653-0.818); 5 years: 0.776 (0.732-0.819) | CGGA: 2 years: 0.675 (0.552-0.799); 3 years: 0.804 (0.751-0.857); 5 years: 0.795 (0.741-0.848) | TCGA: 2 years: 0.634 (0.517-0.75); 3 years: 0.632 (0.458-0.807); 5 years: 0.766 (0.719-0.814) | NA | GEO set: 1.49 (1.01-2.19); CGGA set: 1.83 (1.10-3.05); TCGA set: 1.66 (1.02-2.71) | | Qin [70] | 2020 | GBM | S100A8, CXCL1, and IGLL5 | TCGA: 6 months: 0.604; 1 year: 0.657; 2 years: 0.667; 3 years: 0.667; 5 years: 0.667; | CGGA: 6 months: 0.529; 1 year: 0.572; 2 years: 0.592; 3 years: 0.592; 5 years: 0.592; | — | 0.791 | 2.331 (1.486-3.655) | | Qu [71] | 2020 | Glioma | ULK1, ATG10, ATG16L2, RB1CC1, RUBCNL, PRKN, GSK3B, TBC1D5, PIK3CB, and RAB33B | 1 year: 0.790 | 3 years: 0.861 | 5 years: 0.853 | NA | 1.19 (1.06-1.34) | | Tan [72] | 2020 | Glioma/LGG/GBM | LPAR5, CD163, FPR3, P2RY12, PLAUR, and SIGLEC1 | Glioma: TCGA: 0.784; CGGA: 0.736 | LGG: TCGA: 0.666; CGGA: 0.683 | GBM: TCGA: 0.546; CGGA: 0.622 | NA | NA | | Tian [73] | 2021 | Glioma | IGF2BP3, GNS, RANBP17, SMC4, PTTG1, ST6GALNAC1, TET1, and KLB | TCGA: 3 years: 0.91; 5 years: 0.88; 10 years: 0.83 | CGGA: 3 years: 0.81; 5 years: 0.83; 10 years: 0.85 | — | NA | TCGA: 1.897 (1.147–3.138) | | Wang [74] | 2021 | LGG | GRID2, FOXO1, MYC, PTK6, IKBKE, BIRC5, and TP73 | Training set: 1 year: 0.901 (0.846-0.957); 3 years: 0.848 (0.796-0.900); 5 years: 0.750 (0.684-0.817) | Validation set 1: 1 year: 0.808 (0.693-0.923); 3 years: 0.802 (0.739-0.865); 5 years: 0.674 (0.594-0.753) | Validation set 2: 1 year: 0.830 (0.750-0.910); 3 years: 0.828 (0.752-0.904); 5 years: 0.755 (0.674-0.836) | NA | Training set: 1.714 (1.325–2.217); validation set 1: 1.287 (1.113–1.489); validation set 2: 1.225 (1.012–1.484) | | Wang [22] | 2021 | Glioma | FCER1G, NOX4, TRIM5, SOCS1, APOBEC3C, BIRC5, VIM, TNC, BMP2, CMTM3, IL24, JAG1, CALCRL, HNF4G, and CDK4 | TCGA: 0.886 | GSE43378 validation: 0.688 | — | TCGA: 0.741 | TCGA: 2.461 (1.945-3.113); GSE43378 validation: 6.940 (2.024-23.802) | | Yin [23] | 2020 | LGG | BIRC5, CRLF1, GDF15, LTF, PRLHR, and TNFRSF11B | TCGA: 1 year: 0.89; 3 years: 0.87; 5 years: 0.76 | CGGA: 1 year: 0.72; 3 years: 0.78; 5 years: 0.76 | — | NA | TCGA: 1.92 (1.50–2.47) | | Zhao [75] | 2021 | GBM | CD1D, PTX3, RAC2, ESM1, MDK, TNFSF14, IL2RB, and OSMR | 0.778 | NA | TCGA: 1.269 (1.126–1.430) | | Zuo [76] | 2019 | GBM | CD79B, MAP2K3, IMPDH1, SLC16A3, MPZL3, and APOBR | CGGA: 1 year: 0.699; 2 years: 0.779 | TCGA: 1 year: 0.718; 2 years: 0.704 | — | NA | CGGA: 2.40 (1.42–4.06); TCGA: 1.70 (1.10–2.63) | | The present study | 2021 | Glioma | VEGFA, SOCS3, SPP1, and TGFB2 | TCGA: 1 year: 0.86; 3 years: 0.855; 5 years: 0.812 | CGGA: 1 year: 0.715; 3 years: 0.772; 5 years: 0.759 | — | 0.811 (0.786-0.836) | TCGA: 1.89 (1.252-2.85); CGGA: 2.17 (1.493-3.14) |
|
|
